HL Financial Services LLC Increases Holdings in Johnson & Johnson (JNJ)

HL Financial Services LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,552,187 shares of the company’s stock after acquiring an additional 9,065 shares during the period. Johnson & Johnson comprises 3.5% of HL Financial Services LLC’s portfolio, making the stock its 6th largest holding. HL Financial Services LLC owned approximately 0.06% of Johnson & Johnson worth $198,913,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Enterprise Financial Services Corp raised its position in shares of Johnson & Johnson by 2.4% in the fourth quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock valued at $2,106,000 after buying an additional 358 shares during the last quarter. Welch Investments LLC grew its holdings in Johnson & Johnson by 1.0% in the fourth quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock valued at $5,027,000 after purchasing an additional 373 shares during the period. YHB Investment Advisors Inc. grew its holdings in Johnson & Johnson by 0.5% in the fourth quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock valued at $10,693,000 after purchasing an additional 381 shares during the period. Franklin Parlapiano Turner & Welch LLC grew its holdings in Johnson & Johnson by 1.0% in the fourth quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock valued at $5,363,000 after purchasing an additional 382 shares during the period. Finally, Regent Investment Management LLC grew its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock valued at $6,591,000 after purchasing an additional 385 shares during the period. Institutional investors own 65.96% of the company’s stock.

Get Johnson & Johnson alerts:

JNJ opened at $122.57 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market cap of $328.95 billion, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 1.88 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. During the same period in the previous year, the firm earned $1.83 earnings per share. Johnson & Johnson’s revenue for the quarter was up 12.6% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were paid a dividend of $0.90 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend was Friday, May 25th. Johnson & Johnson’s payout ratio is currently 49.32%.

JNJ has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, April 9th. Jefferies Financial Group set a $153.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, April 13th. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 target price for the company. in a report on Monday, March 26th. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b” rating in a report on Friday, May 18th. Finally, Goldman Sachs Group set a $134.00 target price on shares of Johnson & Johnson and gave the company a “sell” rating in a report on Tuesday, April 17th. Six research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $142.23.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Leave a Reply

Your email address will not be published. Required fields are marked *